Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). (Q53239683)

From Wikidata

Jump to navigation Jump to search

scientific article published on 8 March 2011

Language	Label	Description	Also known as
English	Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study).	scientific article published on 8 March 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21385884%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study) (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21385884%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Evaristo Maiello

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21385884%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Alberto Bardelli

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21385884%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21385884%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

author name string

C Pinto

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21385884%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

F Di Fabio

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21385884%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

S Pini

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21385884%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

T Latiano

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21385884%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

C Aschele

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21385884%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

C Garufi

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21385884%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

A Bochicchio

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21385884%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

G Rosati

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21385884%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

G Aprile

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21385884%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

S Giaquinta

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21385884%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

V Torri

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21385884%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

A Martoni

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21385884%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

publication date

8 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21385884%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21385884%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21385884%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21385884%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

2424-2430

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21385884%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Preoperative versus postoperative chemoradiotherapy for rectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

Chemotherapy with preoperative radiotherapy in rectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

Palliative care and oncology: growing better together.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

Reduced Survival of Rectal Cancer Patients With Increased Tumor Epidermal Growth Factor Receptor Levels

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

The epidermal growth factor receptor mediates radioresistance.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

Sample size tables for exact single-stage phase II designs

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

Prospective study on the FDG-PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ782

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53239683&oldid=1584717528"